Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval

Published: Thursday, October 04, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
HUMIRA is now indicated to treat adult patients with moderate to severe ulcerative colitis who have had an inadequate response to immunosuppressants.

Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary diseases that comprise inflammatory bowel disease (IBD).

HUMIRA works by inhibiting tumor necrosis factor-alpha (TNF-alpha). The UC approval represents the seventh indication for this treatment in the U.S. and makes HUMIRA the first and only self-administered biologic treatment approved for use in this disease.

It is not known if HUMIRA is effective in people with moderate to severe UC who have lost response to or could not tolerate anti-TNF medicines. HUMIRA can be self-administered after proper injection training is received and with proper physician monitoring.

"There is significant unmet medical need in this patient population, which has not seen a new treatment approved in more than seven years," said William J. Sandborn, M.D., division chief, Gastroenterology, University of California, San Diego.

Sandborn continued, "This FDA approval is good news for patients and health care professionals who are seeking another option to manage the disease."

UC is a chronic disease that is marked by inflammation and ulceration in the lining of the colon or large intestine. It is estimated that approximately 700,000 people in the U.S. have UC.

On average, people are diagnosed with UC in their mid-30s, though the disease can occur at any age. Symptoms include abdominal cramping, rectal bleeding, diarrhea, and urgency and frequency to have a bowel movement.

The symptoms of UC tend to come and go, with periods of remission between flare-ups. Treatment may include medication and/or surgery.

It is also important that UC patients properly manage their nutrition because fluids, nutrients and electrolytes can be lost due to rectal bleeding and diarrhea. Additionally, 25 percent of UC patients will require surgery during the course of the disease.

"Since the first FDA approval of HUMIRA in late 2002, Abbott has continued to investigate the medication in multiple conditions with the goal of bringing this treatment option to more patients who may benefit from it," said John M. Leonard, M.D., senior vice president, Global Pharmaceutical Research and Development, Abbott.

Leonard continued, "This approval underscores Abbott's commitment to investing in and advancing our pipeline to benefit patients with IBD."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abbott Completes Acquisition of Topera, Inc.
Company acquire all outstanding equity of Topera for $250 million upfront.
Tuesday, January 06, 2015
Abbott to Acquire Veropharm
The acquisition of the Russian pharmaceutical manufacturer is in keeping with the long term commitment to provide healthcare products to Russian patients.
Monday, June 23, 2014
Partners In Health, Abbott and the Abbott Fund Open Nutrition Facility in Haiti
Facility produces first shipments of locally sourced, therapeutic food to treat severe malnutrition in children.
Monday, November 11, 2013
Abbott Completes Separation of Research-Based Pharmaceuticals Business
Set to deliver industry-leading growth, expanding margins and strong cash flow.
Monday, January 07, 2013
Abbott to Collaborate with Astellas Pharma
The companies will collaborate in a Phase 3 clinical trial for ASP0113, an investigational vaccine for preventing cytomegalovirus reactivation in transplant patients.
Thursday, September 06, 2012
Leading Agent in the Treatment of Psosiasis
Abbott/Eisai's Humira has emerged on top with major-market sales of more than $1.4 billion in 2011.
Tuesday, August 07, 2012
Abbott Licenses Prostate Cancer Biomarkers
The exclusive license from Stanford University for several novel biomarkers could help develop a molecular diagnostic test that differentiates aggressive from nonaggressive prostate cancer.
Wednesday, April 18, 2012
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Abbott Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012
Thursday, March 22, 2012
Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories
FDA will begin implementing the software-based LIMS as part of the agency's initiative to enhance FDA testing laboratories by managing complex processes and analysing the vast amount of information generated.
Thursday, January 19, 2012
Abbott and University of Illinois Establish Center for Nutrition, Learning and Memory
The companies have established the first-ever multi-disciplinary nutrition and cognition research center,. The Center for Nutrition, Learning, and Memory will lead directed and solicited research on the impact of nutrition on learning and memory in the human brain.
Tuesday, December 20, 2011
Abbott and Reata Pharmaceuticals Announce Agreement for Next-Generation Antioxidant Inflammation Modulators
The companies announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Wednesday, December 14, 2011
Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test
Companion diagnostic tests identify specific DNA sequences for cancer immunotherapy antigen.
Tuesday, November 29, 2011
FDA Approves First Supplemental Test for Chagas Disease
The U.S. Food and Drug Administration have approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to T. cruzi, which causes Chagas disease, a serious and potentially fatal parasitic infection.
Monday, November 21, 2011
Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in Rheumatoid Arthritis
Abbott have presented results from a pooled analysis of two pivotal HUMIRA(R) (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta. The study looked at inflammation and structural damage of the joints in early and long-standing RA and their relationship with deteriorating physical function in each stage of the disease.
Wednesday, November 17, 2010
Abbott to Collaborate with Pfizer Inc on Companion Diagnostic Test
Collaboration will select patient candidates for novel investigational non-small cell lung cancer therapy.
Friday, August 28, 2009
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!